SG158736A1 - Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use - Google Patents

Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use

Info

Publication number
SG158736A1
SG158736A1 SG200602178-6A SG2006021786A SG158736A1 SG 158736 A1 SG158736 A1 SG 158736A1 SG 2006021786 A SG2006021786 A SG 2006021786A SG 158736 A1 SG158736 A1 SG 158736A1
Authority
SG
Singapore
Prior art keywords
glp
pharmacological methods
receptor antagonists
peptides acting
receptor agonists
Prior art date
Application number
SG200602178-6A
Other languages
English (en)
Inventor
Pan Clark
Whelan James
Clairmont Kevin B
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of SG158736A1 publication Critical patent/SG158736A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG200602178-6A 2001-10-05 2002-10-04 Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use SG158736A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32773001P 2001-10-05 2001-10-05

Publications (1)

Publication Number Publication Date
SG158736A1 true SG158736A1 (en) 2010-02-26

Family

ID=23277790

Family Applications (2)

Application Number Title Priority Date Filing Date
SG200602178-6A SG158736A1 (en) 2001-10-05 2002-10-04 Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
SG200602184-4A SG149693A1 (en) 2001-10-05 2002-10-04 Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG200602184-4A SG149693A1 (en) 2001-10-05 2002-10-04 Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use

Country Status (27)

Country Link
US (6) US7399745B2 (fr)
EP (1) EP1436330A4 (fr)
JP (1) JP2005508639A (fr)
KR (1) KR20050034580A (fr)
CN (1) CN1326876C (fr)
AR (1) AR036711A1 (fr)
BR (1) BR0213132A (fr)
CA (1) CA2462462A1 (fr)
CO (1) CO5570710A2 (fr)
DO (1) DOP2002000475A (fr)
EC (2) ECSP024346A (fr)
HN (1) HN2002000282A (fr)
HR (1) HRP20040327A2 (fr)
HU (1) HUP0401797A2 (fr)
IL (1) IL160706A0 (fr)
MA (1) MA26228A1 (fr)
MX (1) MXPA04002140A (fr)
MY (1) MY138267A (fr)
NO (1) NO20041792L (fr)
NZ (1) NZ532685A (fr)
PE (1) PE20030850A1 (fr)
PL (1) PL368760A1 (fr)
RU (1) RU2334761C2 (fr)
SG (2) SG158736A1 (fr)
UY (1) UY27469A1 (fr)
WO (1) WO2003040309A2 (fr)
ZA (1) ZA200403322B (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006501820A (ja) * 2002-09-06 2006-01-19 バイエル・フアーマシユーチカルズ・コーポレーシヨン 修飾ｇｌｐ−１受容体アゴニストおよびそれらの薬理学的使用法
EP1605897B1 (fr) 2003-03-19 2012-07-25 Eli Lilly And Company Composes glp-1 a liaison polyethylene glycol
US20050124550A1 (en) * 2003-06-18 2005-06-09 Peri Krishna G. Compounds that modulate the glucagon response and uses thereof
MXPA06006745A (es) 2003-12-18 2006-08-18 Novo Nordisk As Compuestos glp-1 novedosos.
TW200643033A (en) * 2005-03-08 2006-12-16 Chugai Pharmaceutical Co Ltd Conjugate of water-soluble modified hyaluronic acid and glp-1 analogue
JP5755398B2 (ja) 2005-03-18 2015-07-29 ノヴォ ノルディスク アー／エス 伸長されたｇｌｐ−１化合物
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
EP2570133B1 (fr) * 2005-11-07 2016-03-23 Indiana University Research and Technology Corporation Analogues du glucagon dotés de stabilité et solubilité physiologiques
TWI430806B (zh) 2006-09-13 2014-03-21 Smithkline Beecham Corp 用於投與長效降血糖藥劑之方法
RU2477286C2 (ru) * 2007-01-05 2013-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH
AU2008216265B2 (en) * 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
WO2008098693A2 (fr) * 2007-02-16 2008-08-21 Bayer Healthcare Ag Procédé de fabrication
US8980830B2 (en) * 2007-10-30 2015-03-17 Indiana University Research And Technology Corporation Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity
WO2009058662A2 (fr) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Antagonistes du glucagon
WO2009125424A2 (fr) * 2007-12-11 2009-10-15 Cadila Healthcare Limited Peptidomimétiques antagoniste de glucagon et agoniste de glp-1
AU2009210570B2 (en) * 2008-01-30 2014-11-20 Indiana University Research And Technology Corporation Ester-based insulin prodrugs
CL2009000586A1 (es) 2008-03-27 2010-06-04 Lilly Co Eli Fragmento fab o anticuerpo monoclonal humanizado que lo comprende que se une a receptor de glucagon humano/glucr, de rata, de raton, y mono cinomolgus; vector que comprende polinuccleotido codificante; celula huesped que lo comprende; composicion farmaceutica; uso para tratar diabetes tipo 1 o 2, o para la perdida de peso
DK2300035T3 (en) * 2008-06-17 2015-11-16 Univ Indiana Res & Tech Corp Mixed GIP-based agonists for the treatment of metabolic diseases and obesity
EP2300037B1 (fr) * 2008-06-17 2016-03-30 Indiana University Research and Technology Corporation Co-agonistes du récepteur glucagon/glp-1
WO2009155257A1 (fr) * 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Analogues de glucagon présentant des tampons de ph physiologique présentant une solubilité et une stabilité améliorées
KR20110039348A (ko) 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
US8748377B2 (en) 2008-12-10 2014-06-10 Glaxosmithkline Llc Pharmaceutical compositions
CN102325539A (zh) 2008-12-19 2012-01-18 印第安纳大学研究及科技有限公司 基于酰胺的胰高血糖素超家族肽前药
JP5816097B2 (ja) 2009-01-22 2015-11-18 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
WO2010148089A1 (fr) 2009-06-16 2010-12-23 Indiana University Research And Technology Corporation Composés de glucagon actifs sur le récepteur gip
JP6086528B2 (ja) 2009-08-06 2017-03-01 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 長期のインビボ有効性を有する成長ホルモン
GB0917072D0 (en) 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
EP2460527A1 (fr) 2010-01-21 2012-06-06 Sanofi Composition pharmaceutique pour le traitement d'un syndrome métabolique
JP5980689B2 (ja) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
CN118767117A (zh) 2010-01-22 2024-10-15 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
EP2528618A4 (fr) 2010-01-27 2015-05-27 Univ Indiana Res & Tech Corp Conjugués d'antagoniste du glucagon et d'agoniste du gip et compositions pour le traitement de troubles métaboliques et de l'obésité
JP2013525491A (ja) 2010-05-04 2013-06-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 心血管障害を治療または予防し心血管保護を提供する方法
WO2011143208A1 (fr) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Peptides de la superfamille du glucagon manifestant une activité de récepteur couplé à une protéine g
CA2797095A1 (fr) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Peptides de la superfamille des glucagons presentant une activite de recepteur nucleaire d'hormone
RU2580317C2 (ru) 2010-06-24 2016-04-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов
US8507428B2 (en) 2010-12-22 2013-08-13 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
CA2828761C (fr) 2011-03-04 2017-04-04 Becton, Dickinson And Company Dispositif de collecte de sang contenant un inhibiteur de lysophospholipase
BR112013032717A2 (pt) 2011-06-22 2017-01-24 Univ Indiana Res & Tech Corp coagonistas do receptor de glucagon/glp-1
RS56173B1 (sr) 2011-06-22 2017-11-30 Univ Indiana Res & Tech Corp Koagonisti receptora za glukagon/glp-1 receptora
EP2548570A1 (fr) 2011-07-19 2013-01-23 Sanofi Composition pharmaceutique pour le traitement d'un syndrome métabolique
RU2014117678A (ru) 2011-11-17 2015-12-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью
CA2877358A1 (fr) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Analogues du glucagon presentant une activite sur le recepteur du gip
WO2014158900A1 (fr) 2013-03-14 2014-10-02 Indiana University Research And Technology Corporation Conjugués d'insuline-incrétine
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
EP3098235A4 (fr) 2014-01-20 2017-10-18 Hanmi Pharm. Co., Ltd. Insuline à action prolongée et utilisation associée
US10189884B2 (en) 2014-04-28 2019-01-29 The Trustees Of The University Of Pennsylvania Thioamide-modified peptides and uses thereof
WO2015183984A2 (fr) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Compositions thérapeutiques contenant un tocophérol et leurs utilisations
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) * 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
US10183055B2 (en) 2014-07-21 2019-01-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications
US9796759B2 (en) 2014-07-21 2017-10-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides and methods for using and producing the same
ES2822994T3 (es) 2014-09-24 2021-05-05 Univ Indiana Res & Tech Corp Conjugados de incretina-insulina
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
RU2764197C1 (ru) 2016-09-23 2022-01-14 Ханми Фарм. Ко., Лтд. Аналоги инсулина с пониженной аффинностью к рецептору инсулина и их применение
AR111341A1 (es) 2017-03-23 2019-07-03 Hanmi Pharm Ind Co Ltd Un conjugado del análogo de insulina con afinidad reducida para el receptor de insulina y uso del mismo
WO2019160940A1 (fr) 2018-02-13 2019-08-22 Ligand Pharmaceuticals Incorporated Antagonistes de récepteur de glucagon
WO2020115113A1 (fr) 2018-12-04 2020-06-11 Københavns Universitet Peptide de fusion de glp-1 et de neurotensine à double effet agoniste
US12591761B2 (en) 2018-12-05 2026-03-31 Shape Security, Inc. Execution of trained neural networks using a database system
US11934931B2 (en) * 2018-12-17 2024-03-19 Shape Security, Inc. Decision tree training using a database system
WO2020254479A1 (fr) * 2019-06-18 2020-12-24 Fresenius Kabi Ipsum S.R.L. Procédé de fabrication de glucagon
US12406209B1 (en) 2019-06-28 2025-09-02 Shape Security, Inc. Decision tree training using a database system
CN115322794B (zh) 2020-01-11 2025-09-19 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
CN113461785B (zh) * 2021-04-13 2022-10-14 湖南中晟全肽生化有限公司 Glp-1受体激动剂及其应用
CA3224743A1 (fr) 2021-07-14 2023-01-19 Beijing Ql Biopharmaceutical Co., Ltd. Polypeptides de fusion pour troubles metaboliques
WO2024233999A2 (fr) 2023-05-11 2024-11-14 University Hospitals Cleveland Medical Center Thérapie anxiolytique

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991011457A1 (fr) * 1990-01-24 1991-08-08 Buckley Douglas I Analogues de glp-1 utiles dans le traitement du diabete
WO1995018153A1 (fr) * 1993-12-29 1995-07-06 The Rockefeller University Analogues du glucagon avec des remplacements de la serine en position 16 presentant une activite antagoniste
US5846747A (en) * 1992-03-25 1998-12-08 Novo Nordisk A/S Method for detecting glucagon-like peptide-1 antagonists and agonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2100874A1 (fr) * 1991-01-17 1992-07-18 Robert A. Smith Methodes de detection d'antagonistes du glucagon
FI974437A7 (fi) * 1995-06-06 1997-12-05 Pfizer Substituoituja N-(indoli-2-karbonyyli)amideja ja johdannaisia glykogee nifosforylaasi-inhibiittoreina
US5782802A (en) * 1996-03-22 1998-07-21 Vitajet Corporation Multiple use needle-less hypodermic injection device for individual users
US6232310B1 (en) * 1999-03-12 2001-05-15 Novo Nordisk A/S Fused 1,4-thiazine-2-carbonitrile derivatives, their preparation and use
US7041646B2 (en) * 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991011457A1 (fr) * 1990-01-24 1991-08-08 Buckley Douglas I Analogues de glp-1 utiles dans le traitement du diabete
US5846747A (en) * 1992-03-25 1998-12-08 Novo Nordisk A/S Method for detecting glucagon-like peptide-1 antagonists and agonists
WO1995018153A1 (fr) * 1993-12-29 1995-07-06 The Rockefeller University Analogues du glucagon avec des remplacements de la serine en position 16 presentant une activite antagoniste

Also Published As

Publication number Publication date
US20060003417A1 (en) 2006-01-05
EP1436330A2 (fr) 2004-07-14
US20050153890A1 (en) 2005-07-14
IL160706A0 (en) 2004-08-31
PL368760A1 (en) 2005-04-04
RU2334761C2 (ru) 2008-09-27
NO20041792L (no) 2004-07-02
CN1326876C (zh) 2007-07-18
ECSP024346A (es) 2003-05-26
US7488716B2 (en) 2009-02-10
US7399745B2 (en) 2008-07-15
AR036711A1 (es) 2004-09-29
NZ532685A (en) 2006-02-24
MXPA04002140A (es) 2005-03-07
ZA200403322B (en) 2005-05-03
ECSP045094A (es) 2004-06-28
US20060003418A1 (en) 2006-01-05
BR0213132A (pt) 2004-10-19
DOP2002000475A (es) 2003-06-30
SG149693A1 (en) 2009-02-27
CA2462462A1 (fr) 2003-05-15
MY138267A (en) 2009-05-29
RU2004114243A (ru) 2005-05-10
CO5570710A2 (es) 2005-10-31
EP1436330A4 (fr) 2006-01-18
UY27469A1 (es) 2003-04-30
US20050288248A1 (en) 2005-12-29
WO2003040309A2 (fr) 2003-05-15
US20060003934A1 (en) 2006-01-05
KR20050034580A (ko) 2005-04-14
US7494978B2 (en) 2009-02-24
HK1073117A1 (zh) 2005-09-23
PE20030850A1 (es) 2003-10-31
HN2002000282A (es) 2002-12-12
US7488714B2 (en) 2009-02-10
CN1564828A (zh) 2005-01-12
HUP0401797A2 (en) 2006-08-28
HRP20040327A2 (en) 2007-11-30
MA26228A1 (fr) 2004-07-01
US7488715B2 (en) 2009-02-10
JP2005508639A (ja) 2005-04-07
WO2003040309A3 (fr) 2003-12-18
US20060003419A1 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
SG158736A1 (en) Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
IL163067A (en) Isolated heterodimeric cytokine receptor
WO1999000410A3 (fr) Proteines de matricielles extracellulaires humaines
AU2002366384A8 (en) Insulin and igf-1 receptor agonists and antagonists
IL166659A0 (en) Nogo receptor antagonists
EP1539766A4 (fr) Antagonistes des recepteurs du peptide relie au gene de la calcitonine
AU5716901A (en) G protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same
IL165499A (en) Vpac2 receptor agonist polypeptides, pharmaceutical compositions comprising them and uses thereof
WO2003002604A3 (fr) Nouveaux recepteurs couples a la proteine g et leurs sequences d'adn
WO2003018798A3 (fr) Recepteur couple aux proteines g nouvellement identifie et sequences d'adn de ce recepteur
WO2002102839A3 (fr) Nouveaux recepteurs couples a une proteine g et sequences d'adn de ceux-ci
IL176223A0 (en) The glucagon-like peptide-1 receptor agonists, the preparation and the use of the same
DK1363944T3 (da) Höjaffinitetsantagonister for ELR-CXC-kemokiner
AU2002210982A1 (en) Method of screening antiplatelet
WO1998057987A3 (fr) Substrat de la tyrosine kinase du recepteur de l'insuline
WO2003018066A3 (fr) Sequence polynucleotidique genomique murine codant un recepteur couple a la proteine g et methodes d'utilisation associees
ATE470858T1 (de) Opiatrezeptoren
WO2001094415A3 (fr) Recepteurs nucleaires d'hormones
WO1998050546A3 (fr) Proteines associees au recepteur pour l'antigene des cellules b
PL1633859T3 (pl) Linia komórkowa i jej zastosowania
WO2003087331A3 (fr) Recepteur detectant les cations polyvalents dans du saumon atlantique
AR020086A1 (es) Nuevo receptor de angiotensina, preparacion y empleo del mismo
WO2001055392A3 (fr) Recepteurs nucleaires d'hormones
WO2004003133A3 (fr) Molecules signalisant la douleur